title: Immunotherapy for Head and Neck Squamous Cell Carcinoma.
abstract: Although head and neck squamous cell carcinoma has traditionally been considered to be a very immunosuppressive, or at least nonimmunogenic, tumor type, recent results from clinical studies of immune checkpoint blockade strategies have led to resurgence in the enthusiasm for immunotherapeutic approaches. Additional strategies for immunotherapy that are under active investigation include enhancement of cetuximab-mediated antibody-dependent cell-mediated cytotoxicity, tumor vaccines, and engineered T cells for adoptive therapy. All of these studies have early-phase clinical trials under way, and the next several years will be exciting as the results of these studies are reported.
authors.affiliation: Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Stanford, CA 94305, USA.
authors.forename: David W
authors.initials: DW
authors.lastname: Schoppy
authors.affiliation: Division of Head and Neck Surgery, Department of Otolaryngology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: sunwoo@stanford.edu.
authors.forename: John B
authors.initials: JB
authors.lastname: Sunwoo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D000068818:Cetuximab / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods; D058990:Molecular Targeted Therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins; D000077195:Squamous Cell Carcinoma of Head and Neck; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D000068818:Cetuximab
keywords: CTLA-4; Cetuximab; Chimeric antigen receptor; HNSCC; Immunotherapy; PD-1; Vaccine